SLC5A2 and Hyperglycemia: By lowering chronic hyperglycaemia, particularly in the efferent glomerular vessels supplying the renal medulla, SGLT2 inhibition is anticipated to reduce the risk of tubular damage from glucotoxicity and reactive oxygen species, thereby improving tubule viability which may help to mitigate the detrimental impact of AKI [88, 89].